Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

S Benjamin

Showing results (881-890 of 920) with videos related to

Pageof 92
Sort By:
Rare Tumors|August 6, 2024
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohortMichael S Nakazawa, J Andrew Livingston, Maria A Zarzour, et al.
Scientific Reports|September 17, 2024
Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment responseR F Valenzuela, E Duran-Sierra, M Canjirathinkal, et al.
Clinical Sarcoma Research|January 1, 2013
Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapyWei-Lien Wang, Daniela Katz, Dejka M Araujo, et al.
Cancer Research Communications|March 21, 2025
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa ActivationJoel S Benjamin, Abigail Jarret, Shashank Bharill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyAlberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Cancer Treatment Reports|February 1, 1976
Role of DTIC (NSC-45388) in the chemotherapy of sarcomasJ A Gottlieb, R S Benjamin, L H Baker, et al.
Journal of Chemical Information and Modeling|May 26, 2025
Active Learning-Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand-Binding AffinitiesFilipp Gusev, Evgeny Gutkin, Francesco Gentile, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|April 25, 2025
Building a pre-surgical multiparametric-MRI-based morphologic, qualitative, semiquantitative, first and high-order radiomic predictive treatment response model for undifferentiated pleomorphic sarcoma to replace RECISTRaul F Valenzuela, Elvis Duran-Sierra, Mathew Antony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Pageof 92

Showing results (881-890 of 920) with videos related to

Sort By:
Pageof 92
Rare Tumors|August 6, 2024
Clinical characteristics and outcomes of adult alveolar rhabdomyosarcoma patients on first-line systemic therapies: A single-institution cohortMichael S Nakazawa, J Andrew Livingston, Maria A Zarzour, et al.
Scientific Reports|September 17, 2024
Perfusion-weighted imaging with dynamic contrast enhancement (PWI/DCE) morphologic, qualitative, semiquantitative, and radiomics features predicting undifferentiated pleomorphic sarcoma (UPS) treatment responseR F Valenzuela, E Duran-Sierra, M Canjirathinkal, et al.
Clinical Sarcoma Research|January 1, 2013
Extensive adipocytic maturation can be seen in myxoid liposarcomas treated with neoadjuvant doxorubicin and ifosfamide and pre-operative radiation therapyWei-Lien Wang, Daniela Katz, Dejka M Araujo, et al.
Cancer Research Communications|March 21, 2025
23ME-01473, an Fc Effector-Enhanced Anti-ULBP6/2/5 Antibody, Restores NK Cell-Mediated Antitumor Immunity through NKG2D and FcγRIIIa ActivationJoel S Benjamin, Abigail Jarret, Shashank Bharill, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 26, 2011
R1507, a monoclonal antibody to the insulin-like growth factor 1 receptor, in patients with recurrent or refractory Ewing sarcoma family of tumors: results of a phase II Sarcoma Alliance for Research through Collaboration studyAlberto S Pappo, Shreyaskumar R Patel, John Crowley, et al.
Cancers|March 13, 2024
Outcomes of Late-Line Systemic Treatment in GIST: Does Sequence Matter?Prapassorn Thirasastr, Thomas L Sutton, Cissimol P Joseph, et al.
Cancer Treatment Reports|February 1, 1976
Role of DTIC (NSC-45388) in the chemotherapy of sarcomasJ A Gottlieb, R S Benjamin, L H Baker, et al.
Journal of Chemical Information and Modeling|May 26, 2025
Active Learning-Guided Hit Optimization for the Leucine-Rich Repeat Kinase 2 WDR Domain Based on In Silico Ligand-Binding AffinitiesFilipp Gusev, Evgeny Gutkin, Francesco Gentile, et al.
Cancer Imaging : the Official Publication of the International Cancer Imaging Society|April 25, 2025
Building a pre-surgical multiparametric-MRI-based morphologic, qualitative, semiquantitative, first and high-order radiomic predictive treatment response model for undifferentiated pleomorphic sarcoma to replace RECISTRaul F Valenzuela, Elvis Duran-Sierra, Mathew Antony, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|October 26, 2022
Examining Stripes on a Herd of Zebras: Impact of Genomic Matching for Ultrarare Sarcomas in Phase 1 Clinical Trials (SAMBA 102)Justin T Moyers, Roberto Carmagnani Pestana, Jason Roszik, et al.
Pageof 92